Encouraging observed 5-year survival with upfront resection and adjuvant therapy for pancreatic ductal adenocarcinoma in a large contemporary series.

Encouraging observed 5-year survival with upfront resection and adjuvant therapy for pancreatic ductal adenocarcinoma in a large contemporary series Follow-up data included postoperative tumor-directed therapy, disease status, and survival. By multivariable analysis tumor grading, extent of lymph node metastasis, IPMN context, and vascular resections were independently associated with overall and disease-free 5YS. [Extracted from the article]